RTALB FINANCIAL STATEMENTS

RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. — balance sheet, income statement and cash flow trends

RTALBRTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S.

🇹🇷 Turkey · IS · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue269.9 M ₺+24.0%

Gross Profit94.8 M ₺+56.7%

Operating Income-11 M ₺—

EBITDA24.4 M ₺—

Net Income367.9 M ₺+134.0%

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
RTALB	24.0%	35.1%	9.0%	136.3%
OTLK	-2.1%	-360.9%	-18,634.1%	-18,297.5%
PDSB	-100.0%	—	—	—
ATNM	-88.9%	312.2%	-25,150.0%	-26,078.9%
SGMO	-45.8%	100.0%	-339.9%	-356.9%
PMVP	—	—	—	—
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
RTALB	24.0%	35.1%	9.0%	136.3%
ANGEN	11.7%	58.8%	9.8%	-45.0%
TRILC	32.0%	33.8%	28.5%	-2.2%
LKMNH	19.8%	18.8%	26.4%	3.2%
MEDTR	6.5%	30.9%	9.4%	0.2%
SEYKM	-24.8%	29.7%	0.6%	1.3%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity3 B ₺85%
Current Liabilities176.7 M ₺5%
Long-term Liabilities349.1 M ₺10%

Key Figures

YoY change

Total Assets3.5 B ₺+65.1%

Total Liabilities525.9 M ₺+166.8%

Total Equity3 B ₺+54.6%

Cash & ST Investments14.6 M ₺+34.0%

Total Debt36.6 M ₺-77.5%

Net Debt28.6 M ₺-81.7%

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
RTALB	1.21	1.2%	0.90	84.9%
OTLK	0.54	-93.8%	-0.31	-132.4%
PDSB	2.26	407.5%	0.21	15.8%
ATNM	5.89	65.9%	1.79	5.1%
SGMO	0.70	-102.0%	0.07	-31.6%
PMVP	11.14	0.3%	1.19	91.1%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
RTALB	1.21	1.2%	0.90	84.9%
ANGEN	2.31	28.1%	4.71	67.2%
TRILC	0.99	207.6%	2.71	23.5%
LKMNH	0.83	99.0%	1.96	41.6%
MEDTR	3.58	1.0%	-1.64	83.0%
SEYKM	6.82	0.0%	-168.37	88.1%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow157.9 M ₺—

Capital Expenditures-29.2 M ₺—

Free Cash Flow239 M ₺—

Dividends Paid0 ₺—

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
RTALB	58.5%	88.6%	10.8%	42.9%
OTLK	-14,121.8%	-14,121.8%	0.0%	77.2%
PDSB	—	—	—	13,162.3%
ATNM	-25,417.8%	-25,535.6%	117.8%	97.5%
SGMO	-261.4%	-261.8%	0.3%	73.3%
PMVP	—	—	—	95.7%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
RTALB	58.5%	88.6%	10.8%	42.9%
ANGEN	40.2%	-21.2%	61.5%	-89.3%
TRILC	10.9%	-0.3%	11.2%	-505.5%
LKMNH	8.4%	-9.7%	18.2%	264.8%
MEDTR	21.1%	27.9%	6.6%	10,700.8%
SEYKM	33.6%	46.3%	3.1%	2,535.7%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on RTALB

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 3, 26. This content is for informational purposes only and is not investment advice.